Under section 503B of the Federal Food, Drug, and Cosmetic Act, large outsourcing facilities may only compound from bulk active ingredients in two situations: the ingredient appears on the 503B bulks list, meaning FDA has found a clinical need for it, or the finished drug sits on FDA's shortage list at the time of compounding
Individualized dosing: Compounding pharmacies can prepare individualized doses for patients whose clinical needs, as determined by their prescriber, require a formulation not available in an FDA-approved product
Save on Your Weight Loss Drugs with BuzzRx
A clearer, brighter complexion with an even tone
Eye-related side effects Eye-related side effects with Mounjaro are uncommon and mainly affect people with diabetes , particularly those with existing diabetic eye disease
Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]
